In vivo and in vitro estrogenic and progestagenic actions of Tibolone

In vivo and in vitro estrogenic and progestagenic actions of Tibolone

Estrogen and progestin combination in hormone replacement therapy (HRT) increases the incidence of breast cancer, but decreases the endometrial cancer risk of unopposed estrogen. Therefore, a SERM such as Tibolone, that delivers the beneficial, but not the adverse side effects, of steroid hormones w...

Full description

Saved in:
Bibliographic Details
Main Authors: SADARANGANI,ANIL, SALGADO,ANA MARÍA, KATO,SUMIE, PINTO,MAURICIO, CARVAJAL,ANDRÉS, MONSO,CAROLINA, OWEN,GARETH I, VIGIL,PILAR
Language:English
Published: Sociedad de Biología de Chile 2005
Subjects:
breast/endometrium cancer
estrogenic
HRT
progestagenic & tibolone
Online Access:http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602005000200014
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items